Table 1.
Baseline characteristics
|
MS patients n = 140 |
|
|---|---|
| Female sex, n (%) | 97 (69.3) |
| Age, years | 43.5 (12.7) |
| EDSS score, median [IQR] | 2.0 [1.0–3.0] |
|
MS course, n (%) Relapsing Progressive |
124 (88.6) 16 (11.4) |
| Previous SARS-CoV2 infection, n (%) | 4 (2.9) |
|
Vaccine type Pfizer BNT162b2 Moderna mRNA-1273 |
138 (98.6) 2 (1.4) |
| Time from vaccination to blood sample (days), median [IQR] | 31 [29–35] |
| IgG anti-SARS-CoV2 titer (BAU/mL) | 1522.3 (1616.3) |
| IgG anti-SARS-CoV2 titer (BAU/mL) after excluding patients with previous SARS-CoV2 infection | 1508.6 (1627.4) |
| IgG titer above the positivity limit, n (%) | 122 (87.1) |
| IgG titer above the positivity limit after excluding patients with previous SARS-CoV2 infection, n (%) | 118 (86.8) |
| Any side effect, n (%) | 92 (65.7) |
|
DMTs, n (%) No treatment Glatiramer acetate Inferferons Dimethyl fumarate Teriflunomide Fingolimod Ocrelizumab Natalizumab Alemtuzumab Cladribine Azathioprine |
14 (10.0) 11 (7.9) 7 (5.0) 23 (16.4) 11 (7.9) 18 (12.9) 25 (17.9) 18 (12.9) 10 (7.1) 2 (1.4) 1 (0.7) |
All values are reported as mean (standard deviation) unless indicated otherwise
EDSS Expanded Disability Status Scale, IQR interquartile range, MS multiple sclerosis, DMTs disease-modifying therapies